Top Penny Stocks To Watch In October 2026

In the last week, the market has stayed flat, but it is up 13% over the past year, with earnings expected to grow by 17% per annum over the next few years. For those looking to invest in smaller or newer companies, penny stocks — despite their vintage feel — can still offer surprising value when built on solid financial foundations. In this article, we highlight several penny stocks that demonstrate financial strength and potential for long-term growth.

Let's uncover some gems from our specialized screener.

INVE Technologies (INVE)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: INVE Technologies, Inc. develops, manufactures, and supplies specialty IoT products across various regions including the United States, Europe, the Middle East, and the Asia-Pacific with a market cap of $53.80 million.

Operations: The company's revenue is primarily derived from its IoT Business, which generated $24.27 million.

Market Cap: $53.8M

INVE Technologies, Inc., with a market cap of US$53.80 million, is navigating its penny stock status through strategic initiatives and recent executive changes. The company recently provided preliminary earnings guidance for Q3 2026, anticipating revenues between US$2.9 million and US$3.1 million with net income ranging from US$0.4 million to US$0.8 million, indicating potential profitability improvements despite historical losses and negative return on equity (-11.48%). INVE's robust short-term assets (US$132.3M) surpass both short- and long-term liabilities, providing financial stability alongside a seasoned management team following the appointment of James Greenwell as interim CEO.

• Navigate through the intricacies of INVE Technologies with our comprehensive balance sheet health report here.
• Assess INVE Technologies' previous results with our detailed historical performance reports.

TON Strategy (TONX)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: TON Strategy Company, with a market cap of $156.40 million, operates as an interactive video-based social commerce company through its subsidiaries.

Operations: TONX has not reported any revenue segments.

Market Cap: $156.4M

TON Strategy Company, with a market cap of US$156.40 million, has recently shown financial improvement by reporting Q2 2026 sales of US$15.02 million and net income of US$76.75 million, marking a turnaround from previous losses. Despite being debt-free and having short-term assets exceeding liabilities, the company faces challenges with less than a year of cash runway and an inexperienced management team averaging 0.8 years in tenure. Recent developments include significant network upgrades for its TON network infrastructure and the addition to the S&P Global BMI Index, potentially enhancing its market presence and operational capacity.

• Dive into the specifics of TON Strategy here with our thorough balance sheet health report.
• Explore historical data to track TON Strategy's performance over time in our past results report.

Aardvark Therapeutics (AARD)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapeutics for metabolic diseases and has a market cap of $85.35 million.

Operations: Aardvark Therapeutics, Inc. does not currently report any revenue segments.

Market Cap: $85.35M

Aardvark Therapeutics, Inc., with a market cap of US$85.35 million, operates as a pre-revenue entity in the biopharmaceutical sector. The company recently appointed Dr. David Zhang as an independent director, bringing over 25 years of industry expertise which could strengthen strategic oversight. Despite being debt-free and having assets that cover liabilities, Aardvark faces challenges with high volatility and less than a year of cash runway if current cash flow trends persist. Additionally, it is embroiled in a securities class action lawsuit related to its IPO disclosures and has paused its HERO trial due to safety concerns.

• Click here to discover the nuances of Aardvark Therapeutics with our detailed analytical financial health report.
• Evaluate Aardvark Therapeutics' prospects by accessing our earnings growth report.

Summing It All Up

• Reveal the 328 hidden gems among our US Penny Stocks screener with a single click here.
• Ready To Venture Into Other Investment Styles? The end of cancer? These 38 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com